{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:42:42Z","timestamp":1760550162613},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Scientific and Technological Research Council of Turkey (T\u00dcB\u0130TAK 2214-International Research Fellowship Programme"},{"name":"Dr. Khaw's Unrestricted Grant from Gwathmey Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11095-016-2066-2","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T16:56:49Z","timestamp":1480352209000},"page":"352-364","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-1 in Human Breast Cancer"],"prefix":"10.1007","volume":"34","author":[{"given":"Selin Seda","family":"Timur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyhan Neslihan","family":"G\u00fcrsoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130mran","family":"Vural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ban-An","family":"Khaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"2066_CR1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/978-1-60761-416-6_21","volume":"596","author":"XJ Liang","year":"2010","unstructured":"Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol. 2010;596:467\u201388.","journal-title":"Methods Mol Biol"},{"issue":"8","key":"2066_CR2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/anie.200502113","volume":"45","author":"R Haag","year":"2006","unstructured":"Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem. 2006;45(8):1198\u2013215.","journal-title":"Angew Chem"},{"issue":"6","key":"2066_CR3","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.copbio.2011.06.003","volume":"22","author":"F Canal","year":"2011","unstructured":"Canal F, Sanchis J, Vicent MJ. Polymer-drug conjugates as nano-sized medicines. Curr Opin Biotechnol. 2011;22(6):894\u2013900.","journal-title":"Curr Opin Biotechnol"},{"issue":"9","key":"2066_CR4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","volume":"6","author":"R Duncan","year":"2006","unstructured":"Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6(9):688\u2013701.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2066_CR5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.copbio.2011.05.507","volume":"22","author":"R Duncan","year":"2011","unstructured":"Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol. 2011;22(4):492\u2013501.","journal-title":"Curr Opin Biotechnol"},{"key":"2066_CR6","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.2741\/2882","volume":"13","author":"F Greco","year":"2008","unstructured":"Greco F, Vicent MJ. Polymer-drug conjugates: current status and future trends. Front Biosci J Virtual Libr. 2008;13:2744\u201356.","journal-title":"Front Biosci J Virtual Libr"},{"key":"2066_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-00477-3_1","volume":"197","author":"VP Torchilin","year":"2010","unstructured":"Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 2010;197:3\u201353.","journal-title":"Handb Exp Pharmacol"},{"issue":"13","key":"2066_CR8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.addr.2009.05.006","volume":"61","author":"F Greco","year":"2009","unstructured":"Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009;61(13):1203\u201313.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2066_CR9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","volume":"6","author":"S Panowksi","year":"2014","unstructured":"Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014;6(1):34\u201345.","journal-title":"MAbs"},{"key":"2066_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-62703-541-5_1","volume":"1045","author":"I Sassoon","year":"2013","unstructured":"Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol. 2013;1045:1\u201327.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"2066_CR11","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","volume":"74","author":"EC Breij","year":"2014","unstructured":"Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res. 2014;74(4):1214\u201326.","journal-title":"Cancer Res"},{"issue":"7","key":"2066_CR12","first-page":"553","volume":"1","author":"CH Chang","year":"2002","unstructured":"Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther. 2002;1(7):553\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2066_CR13","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1021\/acs.bioconjchem.5b00292","volume":"26","author":"K Westerlund","year":"2015","unstructured":"Westerlund K, Honarvar H, Tolmachev V, Eriksson KA. Design, preparation, and characterization of PNA-based hybridization probes for affibody-molecule-mediated pretargeting. Bioconjug Chem. 2015;26(8):1724\u201336.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"2066_CR14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1021\/bc00019a013","volume":"4","author":"WH Kuijpers","year":"1993","unstructured":"Kuijpers WH, Bos ES, Kaspersen FM, Veeneman GH, van Boeckel CA. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer. Bioconjug Chem. 1993;4(1):94\u2013102.","journal-title":"Bioconjug Chem"},{"issue":"9","key":"2066_CR15","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1021\/acsmedchemlett.5b00265","volume":"6","author":"X Li","year":"2015","unstructured":"Li X, Huang Q, Xiao J, Liu G, Dou S, Rusckowski M, et al. Novel DNA polymer for amplification pretargeting. ACS Med Chem Lett. 2015;6(9):972\u20136.","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"2066_CR16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1089\/nat.2013.0425","volume":"23","author":"P Mallikaratchy","year":"2013","unstructured":"Mallikaratchy P, Gardner J, Nordstrom LUR, Veomett NJ, McDevitt MR, Heaney ML, et al. A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Ther. 2013;23(4):289\u201399.","journal-title":"Nucleic Acid Ther"},{"issue":"10","key":"2066_CR17","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3109\/1061186X.2013.818675","volume":"21","author":"V Patil","year":"2013","unstructured":"Patil V, Gada K, Panwar R, Majewski S, Tekabe Y, Varvarigou A, et al. In vitro demonstration of enhanced prostate cancer toxicity: pretargeting with Bombesin bispecific complexes and targeting with polymer-drug-conjugates. J Drug Target. 2013;21(10):1012\u201321.","journal-title":"J Drug Target"},{"issue":"3","key":"2066_CR18","first-page":"333","volume":"54","author":"G Liu","year":"2010","unstructured":"Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, et al. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector. Q J Nucl Med Mol Imaging. 2010;54(3):333\u201340.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"3","key":"2066_CR19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13277-012-0367-6","volume":"33","author":"RM Sharkey","year":"2012","unstructured":"Sharkey RM, Chang CH, Rossi EA, McBride WJ, Goldenberg DM. Pretargeting: taking an alternate route for localizing radionuclides. Tumor Biol. 2012;33(3):591\u2013600.","journal-title":"Tumor Biol"},{"issue":"9","key":"2066_CR20","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2967\/jnumed.115.159145","volume":"56","author":"SMJ Duijnhoven van","year":"2015","unstructured":"van Duijnhoven SMJ, Rossin R, van den Bosch SM, Wheatcroft MP, Hudson PJ, Robillard MS. Diabody pretargeting with click chemistry in vivo. J Nucl Med. 2015;56(9):1422\u20138.","journal-title":"J Nucl Med"},{"issue":"8","key":"2066_CR21","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00259-014-2738-2","volume":"41","author":"BA Khaw","year":"2014","unstructured":"Khaw BA, Gada KS, Patil V, Panwar R, Mandapati S, Hatefi A, et al. Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts: targeted polymer drug conjugates for cancer diagnosis and therapy. Eur J Nucl Med Mol Imaging. 2014;41(8):1603\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2066_CR22","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/bc8001024","volume":"19","author":"X Chen","year":"2008","unstructured":"Chen X, Dou S, Liu G, Liu X, Wang Y, Chen L, et al. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting. Bioconjug Chem. 2008;19(8):1518\u201325.","journal-title":"Bioconjug Chem"},{"key":"2066_CR23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-8722-5-70","volume":"5","author":"MA Firer","year":"2012","unstructured":"Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012;5:70.","journal-title":"J Hematol Oncol"},{"key":"2066_CR24","doi-asserted-by":"crossref","unstructured":"Zhi Jie Li, CHC. Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. 2012;10(Suppl 1):S1.","DOI":"10.1186\/1479-5876-10-S1-S1"},{"issue":"7","key":"2066_CR25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nm720","volume":"8","author":"P Laakkonen","year":"2002","unstructured":"Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med. 2002;8(7):751\u20135.","journal-title":"Nat Med"},{"issue":"25","key":"2066_CR26","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1073\/pnas.0403317101","volume":"101","author":"P Laakkonen","year":"2004","unstructured":"Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A. 2004;101(25):938\u20139386.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2066_CR27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1196\/annals.1413.003","volume":"1131","author":"P Laakkonen","year":"2008","unstructured":"Laakkonen P, Zhang L, Ruoslahti E. Peptide targeting of tumor lymph vessels. Ann N Y Acad Sci. 2008;1131:37\u201343.","journal-title":"Ann N Y Acad Sci"},{"issue":"7\u20138","key":"2066_CR28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1039\/c0ib00013b","volume":"2","author":"P Laakkonen","year":"2010","unstructured":"Laakkonen P, Vuorinen K. Homing peptides as targeted delivery vehicles. Integr Biol UK. 2010;2(7\u20138):326\u201337.","journal-title":"Integr Biol UK"},{"issue":"17","key":"2066_CR29","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1158\/0008-5472.CAN-07-6752","volume":"68","author":"V Fogal","year":"2008","unstructured":"Fogal V, Zhang L, Krajewski S, Ruoslahti E. Mitochondrial\/cell\u2013 surface protein p32\/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res. 2008;68(17):7210\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"2066_CR30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ultrasmedbio.2013.09.001","volume":"40","author":"F Yan","year":"2014","unstructured":"Yan F, Li X, Jiang C, Jin Q, Zhang Z, Shandas R, et al. A novel microfluidic chip for assessing dynamic adhesion behavior of cell-targeting microbubbles. Ultrasound Med Biol. 2014;40(1):148\u201357.","journal-title":"Ultrasound Med Biol"},{"issue":"4","key":"2066_CR31","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3109\/10837450.2013.795170","volume":"19","author":"RN Gursoy","year":"2014","unstructured":"Gursoy RN, Cevik O. Design, characterization and in vitro evaluation of SMEDDS containing an anticancer peptide, linear LyP-1. Pharm Dev Technol. 2014;19(4):486\u201390.","journal-title":"Pharm Dev Technol"},{"issue":"9","key":"2066_CR32","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1021\/mp3002107","volume":"9","author":"Z Wang","year":"2012","unstructured":"Wang Z, Yu Y, Ma J, Zhang H, Zhang H, Wang X, et al. LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics. Mol Pharm. 2012;9(9):2646\u201357.","journal-title":"Mol Pharm"},{"issue":"1\u20132","key":"2066_CR33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijpharm.2011.03.044","volume":"411","author":"TP Herringson","year":"2011","unstructured":"Herringson TP, Altin JG. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature. Int J Pharm. 2011;411(1\u20132):206\u201314.","journal-title":"Int J Pharm"},{"issue":"2","key":"2066_CR34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1021\/bc400347s","volume":"25","author":"JW Seo","year":"2014","unstructured":"Seo JW, Baek H, Mahakian LM, Kusunose J, Hamzah J, Ruoslahti E, et al. (64)Cu-labeled LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque. Bioconjug Chem. 2014;25(2):231\u20139.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"2066_CR35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1021\/mp400189j","volume":"11","author":"D Miao","year":"2014","unstructured":"Miao D, Jiang M, Liu Z, Gu G, Hu Q, Kang T, et al. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy. Mol Pharm. 2014;11(1):90\u2013101.","journal-title":"Mol Pharm"},{"issue":"4","key":"2066_CR36","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1021\/nn102863y","volume":"5","author":"M Uchida","year":"2011","unstructured":"Uchida M, Kosuge H, Terashima M, Willits DA, Liepold LO, Young MJ, et al. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano. 2011;5(4):2493\u2013502.","journal-title":"ACS Nano"},{"issue":"17\u201318","key":"2066_CR37","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.drudis.2012.04.006","volume":"17","author":"JM Reichert","year":"2012","unstructured":"Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today. 2012;17(17\u201318):954\u201363.","journal-title":"Drug Discov Today"},{"key":"2066_CR38","doi-asserted-by":"crossref","unstructured":"Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35.","DOI":"10.1042\/BSR20150089"},{"issue":"4","key":"2066_CR39","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-12-2072","volume":"73","author":"J Cao","year":"2013","unstructured":"Cao J, Cui S, Li S, Du C, Tian J, Wan S, et al. Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex. Cancer Res. 2013;73(4):1362\u201373.","journal-title":"Cancer Res"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-016-2066-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-016-2066-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-016-2066-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T01:20:12Z","timestamp":1568596812000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-016-2066-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2066"],"URL":"https:\/\/doi.org\/10.1007\/s11095-016-2066-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]}}}